Radoservich M. et al.: Intravenous immunglobulin G: trends in production methods, quality control and quality assurance, Vox Sanguinis (2010) 98: 12-28
Burnouf T et al.: Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia (2003) 9 (1): 24-37
Mehrabi et al.: The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation. Langenbecks Arch Surg (2012) 397:697–710
De Man et al.: Long term application of human polyclonal hepatitis-B immunoglobulin to prevent hepatic allograft infection. Netherl J Medicine (1993) 43: S74-S82
EASL 2017: Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatology (2017): 385-386
Bihl, F. et al.: The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians. Swiss Med. Wkly. (2010) 140 (10-12): 154-159
Volpes R et al: Switchting from intramuscular or intravenous to subcutaneous hepatitis B immunglobuline improves the quality of life of liver transplant recipients. Transplant. Int. (2015) 28:235
Yahyazadeh et al.: Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Intl (2011) 24: 441-450
Klein, C.G. et al.: Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: A prospective, observational, multicenter study. Ann Transplant (2013) 18: 677-684
De Simone, P. et al.: Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study. Transplantation (2016) 100: 1507-1512